OUHSC Research News – Monday, June 13, 2022
Notices and Reminders
SoonerTrack II Update
After careful consideration and in response to resource constraints during the week of July 4th, the Office of Research Administration (ORA) has decided to postpone the SoonerTrack II go-live date to 7/11/22. This change is being made to ensure that adequate support staff from various departments (e.g. PeopleSoft Financials, IT Security, ORA, etc.) is available to assist the Principal Investigators and departmental staff with use of the system during the first week of go-live.
ORA continues work on development and configuration of SoonerTrack II. User Acceptance Testing (UAT) of SoonerTrack II with departmental testers began on 5/31/22 and will continue through 6/17/22. ORA appreciates their time and effort in assisting us with the testing of the system.
Please check your current SoonerTrack tickets for any outstanding statuses that need to be completed/withdrawn prior to the go-live date. If you have any questions, please contact soonertrackhelpdesk@ouhsc.edu.
SoonerTrack II Training Opportunities
Pre-scheduled SoonerTrack II training sessions are available at the following dates and times. All sessions are the same, so register for the one that best fits your schedule. Additional dates will be provided as needed (These sessions will be conducted via Zoom).
- Tuesday, Jun 28, 2022, 10:30 AM - 11:30 AM
Register here
- Wednesday, Jun 29, 2022, 2:30 PM - 3:30 PM
Register here
- Wednesday, Jul 6, 2022, 9:00 AM - 10:00 AM
Register here
- Thursday, Jul 7, 2022, 2:00 PM - 3:00 PM
Register here
- Wednesday, Jul 13, 2022, 10:30 AM - 11:30 AM
Register here
- Wednesday, Jul 20, 2022, 1:30 PM - 2:30 PM
Register here
New Process for Investigators Providing OU Health Patient Data to Outside Entities
If you are providing OU Health patient data as part of your research to any external entity, CRIOC (Clinical Research Informatics Oversight Committee) approval is required. CRIOC composed of legal, compliance, privacy, security, and research officials from the OU Health and Health Sciences Center (HSC) administrations. CRIOC meets at least once per month to review projects requesting to repurpose OU Health data for research. The committee is tasked with weighing any institutional liabilities impacted by usage and exchanges of these data. To enter the review queue, please complete this form: https://redcap.link/crioc_review. You can contact Melisa Tunley (melisa-tunley@ouhsc.edu) for any questions you have about the form or the review processing steps.
NIH Reminder: Action Required for In-Progress RPPR Budget Forms By or Before June 22 (NIH Extramural Nexus) Recipients with in-progress RPPR budget forms, remember to submit by June 22 to avoid having to redo the budget forms. The June 23 release of the RPPR module will include updates to the FORMS-G budget forms. See NOT-OD-22-130 for details. RPPRs submitted on or before June 22 will reflect the FORMS-F budget forms. Due dates for submission of the RPPR remain unchanged.
See https://grants.nih.gov/grants/rppr/index.htm. https://nexus.od.nih.gov/all/2022/06/02/reminder-action-required-for-in-progress-rppr-budget-forms-by-or-before-june-22/
Updated RPPR Instruction Guide Available: An updated RPPR Instruction Guide is now available. The instruction guide reflects changes associated with recently issued guide notices on Other Support and Biosketch format pages, human subjects, Trainee Diversity Report and NRSA childcare costs reporting (see NOT-OD-22-130 for details). Note that a final RPPR Instruction Guide will be published on June 23 to reflect the revised screenshots accompanying the new look and feel of the RPPR module.
NIH Disclosures Guidance
As a reminder, NIH policy now requires applicants and awardees to disclose “all resources made available to a researcher in support of and/or related to all of their research endeavors, regardless of whether or not they have monetary value and regardless of whether they are based at the institution the researcher identifies for the current grant.” Further details on what needs to be disclosed can be found on Notice NOT-OD-19-114.
If you are not sure whether a particular activity should be reported in the biosketch, other support, or annual project reports, check out NIH Disclosures Table. This table provides a list of various activities and when they need to be disclosed.
ORA Notice: CRIOC (Clinical Research Informatics Oversight Committee) Approval
ORA has stablished a process for actively managing requests to share health data with third parties. Regardless of whether or not human subjects are involved in research project, Principal Investigators (PIs) are required to answer the following questions. We are asking these questions manually until SoonerTrack II is up and running with the questions as part of the request form.
Please note that if OU Health patient data is being used, we cannot proceed with posting the Notice of Award (NOA) until the CRIOC approval is received.
- Are you sharing any data that contains Protected Health Information (PHI), Personally Identifiable Information (PII), Limited Data Set (LDS), De-Identified, or Other?
- If no, no further information necessary.
- If yes, answer the following:
- What type of data (please state PHI, PII, LDS, De-Identified, or Other; may be a combination)?
- Does the data being shared come from OU Health patient data?
- With respect to the data being shared, is OUHSC the Provider, Recipient, or Mutual?
- Finally, please provide a description of the data being shared
Workshops and Seminars
Harold Hamm Diabetes Center (HHDC) - Please mark your calendar for the 19th Annual Harold Hamm Diabetes Center Research Symposium. This in-person event will be held on Friday, November 11, 2022 at the Samis Education Center at Children’s Hospital in Oklahoma City. Deadline for abstracts will be announced in the coming weeks. Additional details will be posted on be posted here. Questions? Please email: Katie-Hoefling@ouhsc.edu
OUHSC Funding Opportunities
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).
- A multinational biopharmaceutical company is seeking approaches to treat primary and secondary rheumatology diseases. Small molecule, antibody and gene therapy approaches with potential for “reset” of the immune system that include long term/extended disease and drug-free remission and infrequent dosing intervals are of highest interest. Out of scope: antigen-specific peptide immunotherapy/tolerance, regulatory T cell based approaches, cell based therapy, drug repurposing and immunosuppressants /immunotherapy. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 06/22)
- BASF is seeking biodegradable micro-encapsulation technologies for agricultural active ingredients. Of particular interest are non-microplastic core/shell particles to encapsulate hydrophobic active ingredients. Polymers from natural sources/resources are preferred. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 06/22)
- The Sustainable Materials Division at Faurecia, a tier-one automotive supplier, is seeking approaches for developing low carbon footprint carbon fibers for H2 storage tanks to decrease CO2 emission factors. All types of carbon fiber precursors are of interest; solutions to optimize the carbon fiber production process and solutions to produce a substitute of carbon fiber with similar mechanical properties are of particular interest. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 07/05)
NIH Notices
- Notice of Preapplication Webinar for RFA-CA-22-016, Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional)
(NOT-CA-22-089)
- Notice of Correction to Eligibility for RFA-HD-23-002 NICHD Neonatal Research Network (NRN): Clinical Centers (UG1 Clinical Trial Optional)
(NOT-HD-22-024)
- Solicitation of Nominations for the 2022 National Human Genome Research Institutes Outstanding Award for Enhancing Diversity, Equity, Inclusion, and Accessibility in the Genomics Workforce
(NOT-HG-22-014)
- Notice of Change to RFA-OD-22-003, "Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed)"
(NOT-OD-22-155)
- Notice of Pre-Application Webinar: Harnessing Data Science for Health Discovery and Innovation in Africa: Research Education Program (UE5 Clinical Trial Not Allowed) & Partnership for Innovation Research Projects (U01 Clinical Trial Not Allowed)
(NOT-RM-22-015)
- Request for Information: Inviting comments and suggestions from stakeholders on Pediatric Medical Devices Public-Private Partnership
(NOT-EB-22-008)
- Request for Information (RFI): NINDS/NICHD Workshop on Cerebral Palsy Research
(NOT-NS-22-105)
- Notice of Change in Funding Opportunity RFA-RM-22-015, IND-enabling Studies of Somatic Genome Editing Therapeutic Leads (U19, Clinical Trial Not allowed)
(NOT-RM-22-014)
- Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities (R43/R44)
(NOT-HD-22-009)
- Notice of Special Interest (NOSI): Availability of Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project
(NOT-OD-22-137)
- Notice of Special Interest: Administrative Supplements to NIH-funded T32 and TL1 Training Grants to Better Integrate Behavioral and Social Sciences (BSS) with other Health-Related Sciences
(NOT-OD-22-141)
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
- NIDA, NIMH, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
(PAR-22-181)
Application Receipt Date(s): June 06, 2025
- Measures and Methods for Research on Family Caregivers for People Living with Alzheimers Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)
(RFA-AG-23-022)
Application Receipt Date(s): October 20, 2022
- Measures and Methods for Research on Family Caregivers for People Living with Alzheimers Disease and Related Dementias (AD/ADRD) (R21 Clinical Trial Not Allowed)
(RFA-AG-23-023)
Application Receipt Date(s): October 20, 2022
- Multidisciplinary K12 Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional)
(RFA-DK-22-006)
Application Receipt Date(s): October 27, 2022
- Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required)
(RFA-DK-22-501)
Application Receipt Date(s): October 19, 2022
- Limited Competition for the Continuation of the NIDDK Diabetic Foot Consortium - Clinical Research Units (U01 Clinical Trial Optional)
(RFA-DK-22-509)
Application Receipt Date(s): August 17, 2022
- Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 Clinical Trial Not Allowed)
(RFA-ES-22-003)
Application Receipt Date(s): August 25, 2022
- Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed)
(RFA-NS-22-051)
Application Receipt Date(s): August 10, 2022
Other Funding Opportunities
The Alzheimer’s Drug Discovery Foundation (ADDF): New submission category at this year’s Clinical Trials on Alzheimer’s Disease Conference (CTAD)
Description: The Alzheimer’s Drug Discovery Foundation (ADDF) will lead a new submission category at this year’s Clinical Trials on Alzheimer’s Disease Conference (CTAD), Beyond Amyloid and Tau: Emerging Hypotheses. This category highlights three important areas:
- Diagnostics and Biomarkers – Focusing on the development of accessible and affordable diagnostic tools to help provide an earlier and more accurate diagnosis and disease intervention.
- Geroscience and Alzheimer’s – Highlighting clinical trials focused on the biology of aging, including trials that explore combination therapy and precision medicine.
- Aging and Prevention – Focusing on new research supporting lifestyle intervention as well as drug trials aimed at halting the progression of Alzheimer’s.
Abstract Submission Deadline: June 15, 2022
Link to Full Announcement: https://mailchi.mp/alzdiscovery/2021-ftd-drug-discovery-funding-opportunity-announced-519743?e=8730f4571b
The Mark Foundation for Cancer Research - Endeavor Award and Informational Webinars
Description: The Mark Foundation Endeavor Awards support teams of scientists with diverse areas of expertise to address urgent problems in cancer research. The Endeavor Award program enables teams of three or more investigators to tackle challenges in cancer research that are too large for any single lab to address alone. Endeavor Awards are $3 million grants disbursed over a three-year term.
Informational Webinars: Endeavor Award website
LOI Submission Deadline: July 13, 2022
Link to Full Announcement: https://mailchi.mp/467458b9d14a/our-first-ever-newsletter-13500801?e=2d3e7329ff
The Oklahoma Center for the Advancement of Science and Technology (OCAST) Notice of Funding Opportunity Announcements. OCAST has published a list of Funding Opportunity Announcements for FY 2022. The guidelines for 2022 have not been released yet. Next application submission period opens on August 15, 2022 and closes September 26, 2022. More information about the funding opportunity announcements and additional resources are available here: https://oklahoma.gov/ocast/ogx-overview/funding-opportunities.html.
The Cystic Fibrosis Foundation (CFF): Biological Basis for CF-Related Diabetes Program
Description: The intent of this request for applications is to solicit and fund projects that will improve our understanding of the biological basis for the development and progression of cystic fibrosis-related diabetes as well as to identify potential novel therapeutic strategies to manage and treat the disease.
Application deadline: August 2, 2022
Link to Full Announcement: https://www.cff.org/researchers/biological-basis-cf-related-diabetes-program
The Cystic Fibrosis Foundation (CFF): Path to a Cure -- Collaborative Research Grant
Description: Path to a Cure: Collaborative Research Grants are intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat CF, with an emphasis on advancing CFTR gene repair and replacement approaches. Collaborations that bring new investigators and technologies into the CF research community will be given highest priority. Proposals must include preliminary data to justify support from the Cystic Fibrosis Foundation.
Application deadline: July 14, 2022
Link to Full Announcement: https://www.cff.org/researchers/path-cure-collaborative-research-grant
2022 Michelson Prizes: Next Generation Grants
Description: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development. The Michelson Prizes are awarding research that is highly innovative and impactful, with the potential to be applied across many diseases.
Application deadline: June 26, 2022
Link to Full Announcement: https://www.humanvaccinesproject.org/michelson-prizes/
DoD FY22 Melanoma Research Program (MRP)
Pre-Application (Preproposal): July 8, 2022
Application: October 5, 2022
- Melanoma Academy Scholar Award (MASA)
- Mid-Career Accelerator Award (MCAA)
- Team Science Award (TSA)
- Focused Program Award – Rare Melanomas (FPA)
Pre-Application (Letter of Intent): September 14, 2022
Application: October 5, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/mrp
DoD FY22 Chronic Pain Management Research Program (CPMRP)
- Clinical Exploration Award (CEA)
- Investigator-Initiated Research Award (IIRA)
- Translational Research Award (TRA)
Pre-Application (Preproposal): July 12, 2022
Application: October 13, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/cpmrp
DoD FY22 Lupus Research Program (LRP)
- Idea Award (IA)
- Impact Award (IPA)
- Transformative Vision Award (TVA)
Pre-Application (Letter of Intent): August 16, 2022
Application: September 1, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/lrp
DoD FY22 Vision Research Program (VRP)
- Clinical Trial Award (CTA)
- Focused Translational Team Science Award (FTTSA)
- Investigator-Initiated Research Award (IIRA)
- Translational Research Award (TRA)
Pre-Application (Preproposal): July 15, 2022
Application: November 9, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/vrp
DoD FY22 Rare Cancers Research Program (RCRP)
- Concept Award (CA)
- Idea Development Award (IDA)
- Resource and Community Development Award (RCDA)
Pre-Application (Letter of Intent): July 18, 2022
Application: August 29, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/rcrp
DoD FY22 Pancreatic Cancer Research Program (PCARP)
- Idea Development Award (IDA)
- Translational Research Partnership Award (TRPA)
Pre-Application (Preproposal): July 8, 2022
Application: October 6, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/pcarp
DoD FY22 Multiple Sclerosis Research Program (MSRP)
- Clinical Trial Award (CTA)
- Early Investigator Research Award (EIRA)
- Exploration - Hypothesis Development Award (EHDA)
- Investigator-Initiated Research Award (IIRA)
Pre-Application (Preproposal): June 23, 2022
Application: October 3, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/msrp
DoD FY22 Bone Marrow Failure Research Program (BMFRP)
- Idea Development Award (IDA)
- Investigator-Initiated Research Award (IIRA)
Pre-Application (Preproposal): June 29, 2022
Application: September 23, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/bmfrp
DoD FY22 Prostate Cancer Research Program (PCRP)
- Early Investigator Research Award (EIRA)
- Physician Research Award (PRA)
Pre-Application (LOI): July 7, 2022
Application: July 28, 2022
Letters of Recommendation: August 2, 2022
- Translational Science Award (TSA)
- Health Disparity Research Award (HDRA)
- Data Science Award (DSA)
Pre-Application (LOI): August 4, 2022
Application: August 25, 2022
- Idea Development Award (IDA)
Pre-Application (LOI): July 7, 2022
Application: July 28, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/pcrp
DoD FY22 Peer Reviewed Orthopaedic Research Program (PRORP)
- Applied Research Award (ARA)
- Clinical Trial Award (CTA)
- Clinical Translational Research Award (CTRA)
Pre-Application (Preproposal): June 16, 2022
Application: September 13, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/prorp
DoD FY22 Peer Reviewed Cancer Research Program (PRCRP)
- Behavioral Health Science Award (BHSA)
- Career Development Award (CDA) – Fellow Option
- Career Development Award (CDA) – Virtual Cancer Center Scholar Option
- Translational Team Science Award (TTSA)
Pre-Application (Letter of Intent): July 12, 2022
Application: August 2, 2022
- Convergent Science Cancer Consortium Development Award (CSCCDA)
Pre-Application (Letter of Intent): August 17
Application: September 7, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/prcrp
DoD FY22 Lung Cancer Research Program (LCRP)
- Clinical Translational Research Partnership Award (CTRPA)
Pre-Application (Letter of Intent): July 13, 2022
Letter of Intent is required.
Application: July 27, 2022
Link to Full Announcement: https://cdmrp.army.mil/funding/lcrp